The cover image is based on the article Review Article: Novel Enzyme Therapy Design for Gluten Peptide Digestion Through Exopeptidase Supplementation by Erin R. Bonner et al., https://doi.org/10.1111/apt.70014

In a large systematic review and meta-analysis, exposure to Helicobacter pylori was significantly associated with decreased odds (46%) of eosinophilic oesophagitis and oesophageal eosinophilia.

This study represents the largest and most comprehensive analysis of steatotic liver disease (SLD) prevalence in China to date, incorporating data from both a large population-based cohort (T-SOLID) and an extensive meta-analysis covering 17.4 million individuals.

Exopeptidases are key for completing protein digestion, including proline-rich peptides, and are mostly produced by enterocytes of the intestinal brush border membrane. In coeliac disease, chronic inflammation leads to reduced brush border exopeptidase activity, exacerbating peptide accumulation. Exopeptidase supplementation could support, enhance and/or replace this critical enzyme function in patients.

Guselkumab is safe in doses of up to 100 mg and may reduce inflammation markers in ALD. This study suggests standards for ALD clinical trials, including non-invasive biomarkers and patient selection based on DSM-5 criteria for alcohol use disorder.

This Phase 2b study examined the safety and efficacy of MK-3655, a monoclonal antibody that binds β-klotho and selectively activates the FGFR1c/β-klotho co-receptor complex, in patients with pre-cirrhotic MASH. Treatment with MK-3655 was generally well tolerated and resulted in a modest reduction in liver fat content at 24 weeks.

Our study addresses a critical gap in the current literature by providing the direct comparison of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in reducing major adverse liver outcomes (MALOs) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes (T2D). Our findings suggest that compared to SGLT2i, GLP-1 RA may offer superior long-term liver outcomes for patients with MASLD and T2D.

The lack of increase in portal pressure gradients (PPG) within 24 h after TIPS implantation is associated with poorer outcomes.

Post-TIPS overt hepatic encephalopathy (OHE) significantly increases long-term mortality in cirrhotic patients beyond 24 months without impacting early survival. This study underscores the importance of sustained monitoring and individualised management strategies to improve long-term outcomes following TIPS.

The UC obesity cohort was at an increased risk of the composite outcome of corticosteroid use, change in therapy and colectomy compared to the UC control cohort in patients on advanced therapies including TNFi, vedolizumab, ustekinumab and JAKi.

Patients who achieved HBsAg seroclearance significantly exhibited lower peak alanine aminotransferase (ALT) levels compared to those who did not during the off-therapy period. ALT elevation after NA cessation was not associated with HBsAg seroclearance in the multivariable analyses adjusted for HBV DNA levels at treatment initiation or HBsAg levels at treatment cessation.

For patients with difficultlty in differentiation diagnosis, targeted next-generation sequencing can facilitate the rapid diagnosis of intestinal tuberculosis and effectively discriminate it from Crohn's disease with latent tuberculosis infection in clinical practice.

This study shows a markedly reduced risk of de novo HCC among patients with chronic HCV–related compensated cirrhosis who received DAA treatment compared to those who remained untreated. There were no differences in HCC risk between DAA-treated and IFN-treated patients.